GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » Cyclically Adjusted Price-to-FCF

Acasti Pharma (TSXV:ACST) Cyclically Adjusted Price-to-FCF : (As of May. 01, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Acasti Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Acasti Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Cyclically Adjusted Price-to-FCF Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acasti Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Acasti Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acasti Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's Cyclically Adjusted Price-to-FCF falls into.



Acasti Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Acasti Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Acasti Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.057/125.4675*125.4675
=-0.057

Current CPI (Dec. 2023) = 125.4675.

Acasti Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201311 -0.863 97.182 -1.114
201402 -3.593 98.051 -4.598
201405 -0.383 99.394 -0.483
201408 -1.431 99.315 -1.808
201411 -1.661 99.078 -2.103
201502 -1.656 99.078 -2.097
201505 -0.805 100.263 -1.007
201508 -1.745 100.579 -2.177
201511 -1.308 100.421 -1.634
201602 -1.284 100.421 -1.604
201605 -1.916 101.765 -2.362
201608 -1.078 101.686 -1.330
201611 -1.881 101.607 -2.323
201706 -0.970 103.029 -1.181
201709 -1.158 103.345 -1.406
201712 -2.449 103.345 -2.973
201803 -1.351 105.004 -1.614
201806 -1.484 105.557 -1.764
201809 -1.499 105.636 -1.780
201812 -1.131 105.399 -1.346
201903 -1.174 106.979 -1.377
201906 -0.925 107.690 -1.078
201909 -0.786 107.611 -0.916
201912 -0.893 107.769 -1.040
202003 -0.364 107.927 -0.423
202006 -0.503 108.401 -0.582
202009 -0.469 108.164 -0.544
202012 -0.431 108.559 -0.498
202103 -0.085 110.298 -0.097
202106 -0.160 111.720 -0.180
202109 -0.236 112.905 -0.262
202112 -0.132 113.774 -0.146
202203 -0.090 117.646 -0.096
202206 -0.157 120.806 -0.163
202209 -0.103 120.648 -0.107
202212 -0.113 120.964 -0.117
202303 -0.102 122.702 -0.104
202306 -0.186 124.203 -0.188
202309 -0.064 125.230 -0.064
202312 -0.057 125.468 -0.057

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acasti Pharma  (TSXV:ACST) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Acasti Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (TSXV:ACST) Business Description

Industry
Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Acasti Pharma (TSXV:ACST) Headlines

From GuruFocus

Acasti Pharma Reports First Quarter 2023 Operational Results

By PurpleRose PurpleRose 08-11-2022

Acasti Pharma Recognizes Rare Disease Day

By PRNewswire PRNewswire 02-28-2023

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

By Stock market mentor Stock market mentor 01-24-2023